Analytical Data
-
Gene name
MIP-3 beta/CCL19
- Application
-
Alternative Names
CCL19; CKb11; ELC; MIP3-B; SCYA19; Chemokine C-C-Motif Ligand 19; Beta Chemokine Exodus-3; CK Beta-11; EBI1-Ligand Chemokine; Small Inducible Cytokine Subfamily A19
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 97% as determined by SDS-PAGE.
-
Uniprot
Q99731
-
Expression Region
Gly22~Ser98
-
Protein Length
Partial
-
Molecular Weight
14kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MIP-3 beta, also known as CCL19, is a chemokine that plays a crucial role in the immune system by regulating the migration of immune cells, particularly lymphocytes, to sites of inflammation and lymphoid tissues. It primarily interacts with the CCR7 receptor, which is vital for the proper functioning of T cells and dendritic cells in immune responses. Research on MIP-3 beta/CCL19 has gained significant attention due to its potential applications in immunotherapy, vaccine development, and understanding autoimmune diseases. The interest in recombinant MIP-3 beta/CCL19 proteins has increased, as these proteins can be utilized to enhance immune responses or to study lymphocyte trafficking in various pathological conditions. By producing recombinant forms of CCL19, researchers aim to investigate its structural properties, understand its signaling mechanisms, and explore its therapeutic potential in enhancing immune responses or modulating inflammatory conditions. Furthermore, understanding the role of CCL19 in the tumor microenvironment may provide insights into cancer immunology and aid in developing novel cancer treatments. Overall, the study of recombinant MIP-3 beta/CCL19 is instrumental in advancing our knowledge of immune cell regulation and developing new strategies for immune modulation in various diseases.
